<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT201204145172N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2012-07-07</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>Effect of a new drug ( Methyl-Naltrexone) in reducing urinary complication after use of Morphine</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the effect of Methyl-Naltrexone in reducing urinary retention after orthopedic surgeries under spinal anesthesia by Bupivacaine and Morphine</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2012-07-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>70</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/5533</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Urinary Retention.</hc_freetext>
      <i_freetext>Intervention 1: As usual anesthetic protocol,10 mg intrathecal bupivacaine 0.5%  and 0.1 are injected; immediately, 12mg  methyl Naltrexone  subcutaneously (by a trained nurse who is unaware of any drugs) will be administered to patients in the first group.&#13;
Then during surgery and 24 hours after it, symptoms such as urinary retention, nausea and vomiting, itching, respiratory suppression and decreased level of consciousness are investigated. Intervention 2: As usual anesthetic protocol,10 mg intrathecal bupivacaine 0.5% and 0.1 are injected; immediately, placebo subcutaneously (by a trained nurse who is unaware of any drugs) will be administered to patients in the second group. Then during surgery and 24 hours after it, symptoms such as urinary retention, nausea and vomiting, itching, respiratory suppression and decreased level of consciousness are investigated.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Saman Asadi, MD</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Anestheiology office, Shahid Faghihi Hospital, Shiraz</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 71 1231 8072</telephone>
        <email>asadisa@sums.ac.ir</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Farid Zand, MD</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Anesthesiology office, Shahid Faghihi Hospital, Shiraz</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 71 1231 8072</telephone>
        <email>zandf@sums.ac.ir</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria:18 – 50 years old patient ; planned orthopedic surgery on lower Extremities; usual criteria for spinal anesthesia         &#13;
&#13;
Exclusion Criteria :   Peri-op Int. folley; Genito-urinary problems (Benign prostatic hyperplasia, Urinary stone, Renal failure, … ); Addiction (in 6 mounts before operation) ; Use of opioids in 12 hours before operation; Neurologic Disease (stroke, alcohol/diabete neuropathies, cerebral palsy, spinal lesions, multiple sclerosis, poly myositis ) ;  Drugs ( anti-cholinergics, β-blockers, Sympathomimetics, α-agonists/antagonists)</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>50 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N39.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Disorder of urinary system, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>As usual anesthetic protocol,10 mg intrathecal bupivacaine 0.5%  and 0.1 are injected; immediately, 12mg  methyl Naltrexone  subcutaneously (by a trained nurse who is unaware of any drugs) will be administered to patients in the first group.&#13;
Then during surgery and 24 hours after it, symptoms such as urinary retention, nausea and vomiting, itching, respiratory suppression and decreased level of consciousness are investigated</i_keyword>
      <i_keyword>As usual anesthetic protocol,10 mg intrathecal bupivacaine 0.5% and 0.1 are injected; immediately, placebo subcutaneously (by a trained nurse who is unaware of any drugs) will be administered to patients in the second group. Then during surgery and 24 hours after it, symptoms such as urinary retention, nausea and vomiting, itching, respiratory suppression and decreased level of consciousness are investigated</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Urinary retention. Timepoint: every 1 hour till 24 hours after surgery. Method of measurement: By a questionnaire of urinary retention: a) the patient's inability to pass urine after surgery, despite feeling a need to urinating for half an hour and leaving every amount of urine after catheterization. B) inability to pass urine for 12 hours after surgery, without feeling a need to urinating and leaving at least 600 cc of urine after catheterization.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Itching. Timepoint: every 1 hour till 24 hours after surgery. Method of measurement: By a questionnaire of itching: incidence of itching to the extent that the patient seek treatment.</sec_outcome>
      <sec_outcome>Nausea, vomiting. Timepoint: every 1 hour till 24 hours after surgery. Method of measurement: By a questionnaire of nausea and vomiting: a) the incidence of nausea in the interval 4 to 24 hours after surgery (each of which is questioned by a trained nurse), b)vomit  the stomach contents in 4 to 24 hours after surgery.</sec_outcome>
      <sec_outcome>Respiratory suppression. Timepoint: every 1 hour till 24 hours after surgery. Method of measurement: By a questionnaire of suppressed breathing, reduced respiratory rate less than 8 per minutes for 24 hours after surgery (each hour can be recorded by trained nurses).</sec_outcome>
      <sec_outcome>Decreased level of consciousness. Timepoint: every 1 hour till 24 hours after surgery. Method of measurement: By a questionnaire of decreased level of consciousness: drowsiness or dizziness that each hour until 24 hours after surgery are recorded by trained nurses.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2012-01-21</approval_date>
        <contact_name>Ethics committee of Shiraz University of Medical Sciences</contact_name>
        <contact_address>Shiraz University of Medical Sciences Shiraz  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
